Immunosenescence Drug Pipeline — PatSnap Eureka
Thymic Rejuvenation, IL-7 & Aged Immune System Restoration
Immunosenescence drives infection susceptibility, vaccine failure, and malignancy risk in the elderly — a population projected to reach 1.6 billion by 2050. Explore the patent and literature signals shaping the next generation of immune restoration therapies.
The Multi-Layered Pathophysiology of Immunosenescence
Retrieved patent and literature results converge on a multi-layered pathophysiology. The primary structural lesion is thymic involution — age-associated atrophy of the thymic cortex and medulla — which curtails the export of recent thymic emigrants (RTEs) and naïve T cells, progressively collapsing T cell receptor (TCR) repertoire diversity. As described in work from Texas Christian University Fort Worth and Ben-Gurion University, thymic involution initiates cumulative dysregulation of the CD4 T cell landscape, contributing to impaired tissue repair and chronic sterile inflammation.
Beyond the thymus, silencing of the IL7R gene and downstream JAK1/JAK3/IL-2Rγ signaling components has been identified as a key aging biomarker. Work from the University of Connecticut identified the IL-7 signaling pathway as a chromatin-level aging signature in CD8+ memory T cells. The IL7R gene network — including IL2RG, IL7, TSLP, CRLF2, JAK1, JAK3 — was associated with familial longevity and healthy ageing in the Leiden Longevity Study.
Accumulation of senescent cells with Senescence-Associated Secretory Phenotype (SASP) — secreting pro-inflammatory cytokines including TGF-β and IL-6 — drives inflammaging. Key molecular markers include p16INK4a, SA-β-galactosidase, TGF-β, and IL-6. Constitutive NF-κB activation is retrieved as a major driver of cellular senescence and stem cell dysfunction, while a distinct PD-1+CD153+ CD4+ memory T cell population constitutively secreting osteopontin has been identified as a bona fide age-dependent mediator of immunosenescence. Explore the full IP analytics landscape for this target space on PatSnap.
Six Approaches to Aged Immune System Restoration
Patent and literature signals map six distinct therapeutic categories targeting immunosenescence, from structural thymic interventions to adoptive cell therapies and small molecule senolytics.
Thymic Rejuvenation Strategies
Sex steroid ablation (SSA), keratinocyte growth factor (KGF), fetal thymus transplantation, thymosin Beta-4, and mitochondria-targeted antioxidant SkQ1 (at 250 nmol/kg/day) have all been retrieved as agents capable of inhibiting age-dependent thymic involution. OHSU Vaccine and Gene Therapy Institute work showed SSA robustly rejuvenates thymic architecture, though benefits to peripheral naïve T cell pools were constrained by stromal barriers in aged lymph nodes.
Predominantly preclinicalIL-7 and Cytokine-Based T Cell Expansion
IL-7/anti-IL-7 monoclonal antibody complexes (IL-7C) induced more than fourfold increase in total T cells and twofold increase in antigen-specific CD8 T cells in aged mice, restoring immune defense against West Nile virus. IL-21 stimulated de novo thymopoiesis — expanding early thymic progenitors, DN and DP thymocytes, and thymic epithelial cells — increasing peripheral RTE output. A Merck Patent GmbH EP filing covers NHS-IL12 combined with IL-7 (FcIL-7) and/or IL-2 for cancer immunotherapy.
Advanced preclinical + patent-filedSenolytic and Senomorphic Pharmacology
Dasatinib, navitoclax, and venetoclax are front-line senolytics in preclinical models. UConn Center on Aging work showed senolytics restored CD4 T helper differentiation during influenza infection in aged mice toward a more youthful phenotype. SR12343 — a small molecule disrupting the IKKβ-NEMO protein-protein interaction — reduced SA-β-galactosidase activity and SASP markers in accelerated aging mouse models. HCW9218 simultaneously neutralizes TGF-β and stimulates immune cell subsets, durably reducing senescent cell burden in aged and diabetic mice.
Small human trials underwayNK Cell–Based Immune Senolysis
NK cells exhibit direct cytotoxic activity against senescent cells in vitro, enhanced further by dopamine (via D1-like receptors) and the dopamine-releasing peptide Acein. An open-label randomized controlled trial (37 participants, 32 receiving intravenous NK cell infusions) from Changzheng Hospital demonstrated reduction in circulating senescent and exhausted T cells (CD28−, CD57+) within 4 weeks post-infusion — the clearest clinical-stage signal in this dataset. Explore life sciences IP intelligence for NK cell therapy patents.
Early-phase human trialStem Cell and Hematopoietic Reconstitution
Heterochronic non-myeloablative bone marrow transplantation (BMT) reconstituted immune architecture, reduced frailty, and extended lifespan in aged murine recipients. Mesenchymal stem cell (MSC) transplantation leverages low immunogenicity and capacity to modulate T and B cell differentiation. Exosomal miRNA cargo (targeting PAX and PPMIF) from young cells partially reprogrammed aged hematopoietic cells, restoring lymphoid:myeloid ratio in humanized mice. Extended heterochronic parabiosis durably reduced biological age in blood and liver by epigenetic clock measures.
Animal models + early clinical contextMicronutrient and Dietary Interventions
Zinc supplementation corrected CREMα-mediated IL-2 suppression in aged human lymphocytes (RWTH Aachen, 2022). N-acetylcysteine and Vitamin C improved T cell commitment to immunological memory in aged mice. Caloric restriction (but not resveratrol) maintained OX40 agonist-mediated anti-tumor immunity in aged mice. These accessible interventions represent complementary modulators of immunosenescence pathways.
Preclinical to early human observationalKey Quantitative Signals from the Pipeline
Patent and literature data extracted via PatSnap Eureka, illustrating development stage distribution and IL-7 complex efficacy signals in aged preclinical models.
Immunosenescence Pipeline: Development Stage Distribution
Across retrieved records, the majority of immunosenescence modalities remain in preclinical stages, with limited clinical-stage signals — reflecting early-phase commercial IP crystallization.
IL-7 Complex: T Cell Expansion in Aged Mice (Fold Increase)
IL-7/anti-IL-7 mAb complexes produced more than fourfold increase in total T cells and twofold increase in antigen-specific CD8 T cells in aged C57BL/6 mice (University of Arizona, 2022).
Key Targets and Therapeutic Rationale
Each target below is supported by retrieved patent or literature evidence. Rationale is derived directly from the retrieved dataset — no extrapolation.
| Target / Pathway | Therapeutic Rationale (Retrieved Evidence) |
|---|---|
| IL-7 / IL-7R / JAK1/JAK3 | Silenced with aging at chromatin level; IL-7C complexes restore naïve T cell pool and antigen-specific CD8 responses; IL7R network expression associates with longevity in Leiden Longevity Study |
| Thymic epithelial cells (TECs) / ETP expansion | IL-21 expands TECs and early thymic progenitors in aged thymus, driving increased peripheral RTE output without altering bone marrow progenitor frequencies |
| DAF-2/Insulin-IGF-1 → DAF-16/FOXO / HSF-1 / ZIP-10 | Genetic inhibition of IIS pathway drastically delays immunosenescence in C. elegans; conserved pathway relevant to mammalian immune aging |
| NF-κB / IKKβ-NEMO | SR12343 disrupts IKKβ-NEMO interaction, reducing SASP and senescence markers; rare NF-κB variants enriched in centenarians |
Track emerging immunosenescence targets with AI
PatSnap Eureka monitors patent filings and literature across all molecular targets in real time.
From Bench to Bedside: Key Human Evidence
Retrieved results contain limited but notable clinical signals across NK cell therapy, senolytics, and vaccine immunosenescence biomarkers.
NK Cell Infusion RCT (n=37)
An open-label randomized controlled trial at Changzheng Hospital, Shanghai (37 participants, 32 receiving intravenous NK cell infusions) demonstrated reduction in circulating senescent and exhausted T cells (CD28−, CD57+) within 4 weeks post-infusion. This is the most proximate clinical signal in this dataset for immune senolytic therapy. NK cell cytotoxicity was enhanced further by dopamine (via D1-like receptors) and the dopamine-releasing peptide Acein.
Senolytics in Small Human Trials
Retrieved results note that senotherapeutics (senolytics/senomorphics) have undergone small clinical trials demonstrating benefits and that multiple clinical trials are under way, though specific trial data are not detailed in the retrieved records. Dasatinib + quercetin combinations represent the leading clinical-stage senolytic approach. Access the PatSnap customer evidence base for real-world IP intelligence use cases.
Zoster Vaccine Senescence Biomarkers (n=399)
A University of Colorado Denver study identified specific immune senescence markers — CD28−, CD57+, PD-1+ T cells; IL-10, TGF-β — as independent predictors of reduced zoster vaccine immunogenicity in 399 adults ≥50 years, providing actionable clinical biomarker data for immunosenescence-targeted vaccine strategies.
Allogeneic HCT in Older Patients
Weill Cornell Medical College data indicate that older patients are increasingly considered for allogeneic hematopoietic cell transplantation (HCT), with thymic dysfunction cited as a major obstacle. This represents an ongoing clinical translation context for thymic rejuvenation interventions and underscores the urgency of restoring naïve T cell export in elderly transplant recipients.
Academic-Led Research with Emerging Commercial Signals
In this dataset, innovation activity is predominantly literature-driven, with a very limited patent signal. Only a single patent filing was retrieved — Merck Patent GmbH (EP jurisdiction) — covering NHS-IL12 combined with IL-7 (FcIL-7) and/or IL-2 for cancer immunotherapy. This pattern suggests the immunosenescence rejuvenation field remains largely in the academic and preclinical research phase with limited commercial IP crystallization to date.
Key academic contributors include the University of Arizona (IL-7C naïve CD8 T cell restoration), Université de Montréal (IL-21 thymostimulation), OHSU Vaccine and Gene Therapy Institute (KGF and SSA thymic rejuvenation), UConn Center on Aging (IL-7R chromatin aging signature; senolytic CD4 T cell effects), KAIST (IIS/DAF-2/ZIP-10 pathway), and Mayo Clinic/Duke Molecular Physiology Institute (SR12343 IKK/NF-κB inhibitor; heterochronic parabiosis). PubMed and EPO searches corroborate the academic dominance of this pipeline.
Emerging combination directions include: cytokine combinatorics (IL-12 + IL-7 ± IL-2), senolysis + stem cell rejuvenation (Yamanaka factor expression + targeted SnC clearance), NK cell infusion + dopamine-releasing peptides, and exosomal miRNA cargo delivery for hematopoietic reprogramming. The PatSnap analytics platform enables monitoring of these convergent multi-modal strategies across patent and literature databases.
Convergent Multi-Modal Strategies in the Pipeline
Signals in this dataset suggest five convergent combination approaches that leverage complementary mechanisms of immune restoration.
Combination Approach Readiness: Evidence Strength by Strategy
Qualitative evidence strength for five retrieved combination immunosenescence strategies, based on patent + literature signal density in this dataset.
Key Pathway Targets: Therapeutic Intervention Points
Process diagram mapping the primary intervention points across the immunosenescence cascade, from thymic output to peripheral immune competence.
Immunosenescence Drug Pipeline — key questions answered
Immunosenescence is the progressive deterioration of immune competence with age, driving increased susceptibility to infection, malignancy, and vaccine failure in the elderly — a population projected to reach 1.6 billion globally by 2050. Therapeutic restoration of aged immune function has emerged as a tractable objective, with approaches ranging from thymic rejuvenation and cytokine-based naïve T cell expansion to senolytic clearance of senescent immune cells and stem cell-based hematopoietic reconstitution.
IL-7/anti-IL-7 monoclonal antibody complexes (IL-7C) administered to aged C57BL/6 mice induced robust T cell expansion — more than fourfold increase in total T cells and twofold increase in antigen-specific CD8 T cells — restoring immune defense against West Nile virus. Improvement tracked quantitatively with naïve CD8 T cell numbers. IL-7/mAb complexes were also shown to restore naïve T cell homeostatic proliferation in aged mice by compensating for structural deficiencies in lymph node T cell zones and homing chemokine expression.
Thymic involution — age-associated atrophy of the thymic cortex and medulla — curtails the export of recent thymic emigrants (RTEs) and naïve T cells, progressively collapsing T cell receptor (TCR) repertoire diversity. Thymic involution initiates cumulative dysregulation of the CD4 T cell landscape, contributing to impaired tissue repair and chronic sterile inflammation.
Dasatinib, navitoclax, and venetoclax are retrieved as front-line senolytics in preclinical models. A zebrafish study demonstrated senescence-independent anti-inflammatory activity of these agents in chronic inflammation models, and UConn Center on Aging work showed senolytics restored CD4 T helper differentiation during influenza infection in aged mice toward a more youthful phenotype. Senolytics (dasatinib + quercetin) have progressed to small human clinical trials per retrieved literature context.
An open-label randomized controlled trial (Changzheng Hospital, 37 participants, 32 receiving intravenous NK cell infusions) demonstrated reduction in circulating senescent and exhausted T cells (CD28−, CD57+) within 4 weeks post-infusion. NK cells exhibited direct cytotoxic activity against senescent cells in vitro, enhanced further by dopamine (via D1-like receptors) and the dopamine-releasing peptide Acein.
Innovation activity is predominantly literature-driven (academic research papers), with a very limited patent signal. Only a single patent filing was retrieved (Merck Patent GmbH, EP jurisdiction). This pattern suggests the immunosenescence rejuvenation field remains largely in the academic and preclinical research phase with limited commercial IP crystallization to date, though the Merck filing on IL-12/IL-7/IL-2 cytokine combinations signals early commercial translation.
Still have questions? Let PatSnap Eureka answer them for you.
Ask PatSnap Eureka About This PipelineAccelerate Your Immunosenescence Drug Discovery
Join 18,000+ innovators already using PatSnap Eureka to accelerate their R&D. Search patents, map molecular targets, and track the IL-7, thymic rejuvenation, and senolytic pipeline in real time.
References
- Contributions of Age-Related Thymic Involution to Immunosenescence and Inflammaging — Texas Christian University Fort Worth / Ben-Gurion University
- Thymus involution sets the clock of the aging T-cell landscape — Ben-Gurion University
- The chromatin accessibility signature of human immune aging stems from CD8+ T cells — University of Connecticut
- IL7R gene expression network associates with human healthy ageing — VU University Medical Center Amsterdam (2015)
- Reduction of insulin/IGF-1 receptor rejuvenates immunity via positive feedback circuit — Princeton University / KAIST
- Novel small molecule inhibition of IKK/NF-κB activation reduces markers of senescence and improves healthspan — Mayo Clinic / Duke Molecular Physiology (2021)
- The impact of senescence-associated T cells on immunosenescence and age-related disorders
- Short-term zinc supplementation of zinc-deficient seniors counteracts CREMα-mediated IL-2 suppression — RWTH Aachen (2022)
- Lymph nodes as barriers to T-cell rejuvenation in aging mice and nonhuman primates — OHSU Vaccine and Gene Therapy Institute (2018)
- Impact of Sex Steroid Ablation on Viral, Tumour and Vaccine Responses in Aged Mice — University of Queensland (2012)
- Fetal thymus graft enables recovery from age-related hearing loss and expansion of CD4-Positive T cells — Kansai Medical University (2015)
- Utilizing Developmentally Essential Secreted Peptides Such as Thymosin Beta-4 to Remind the Adult Organs of Their Embryonic State — University of Pécs (2021)
- Mitochondria-targeted antioxidant SkQ1 inhibits age-dependent involution of the thymus in normal and senescence-prone rats — Novosibirsk State University (2009)
- Quantitative restoration of immune defense in old animals determined by naive antigen-specific CD8 T-cell numbers — University of Arizona (2022)
- The aged lymphoid tissue environment fails to support naïve T cell homeostasis — The Scripps Research Institute (2016)
- Interleukin-21 administration to aged mice rejuvenates their peripheral T-cell pool by triggering de novo thymopoiesis — Université de Montréal (2016)
- Senescence-induced changes in CD4 T cell differentiation can be alleviated by treatment with senolytics — UConn Center on Aging (2021)
- Senescence-Independent Anti-Inflammatory Activity of the Senolytic Drugs Dasatinib, Navitoclax, and Venetoclax in Zebrafish Models — Universidad Católica de Murcia (2022)
- Immunotherapeutic approach to reduce senescent cells and alleviate senescence-associated secretory phenotype in mice — HCW Biologics Inc. (2023)
- Combining adoptive NK cell infusion with a dopamine-releasing peptide reduces senescent cells in aged mice — China Pharmaceutical University (2022)
- Characterization of age-related immune features after autologous NK cell infusion: RCT Protocol — Changzheng Hospital, Shanghai (2022)
- The Influence of Heterochronic Non-Myeloablative Bone Marrow Transplantation on the Immune System, Frailty, General Health, and Longevity — Blood Transfusion Centre of Slovenia (2022)
- Exosome-mediated hematopoietic rejuvenation in a humanized mouse model — NJMS-Molecular Core (2020)
- Multi-omic rejuvenation and lifespan extension upon exposure to youthful circulation — Duke University (2021)
- Immune Senescence Factors Associated with the Immunogenicity of a Live Attenuated Zoster Vaccine in Older Adults — University of Colorado Denver (2017)
- Combining Stem Cell Rejuvenation and Senescence Targeting to Synergistically Extend Lifespan — Yale-NUS College (2022)
- National Institutes of Health (NIH) — Aging and Immunology Research
- PubMed — National Library of Medicine
- European Patent Office (EPO)
All data and statistics on this page are sourced from the references above and from PatSnap's proprietary innovation intelligence platform. This report is derived from a limited set of patent and literature records retrieved across targeted searches and represents a snapshot of innovation signals within this dataset only.
PatSnap Eureka searches patents and research to answer instantly.